Literature DB >> 36176663

The Many Lives of PCSK9: Therapeutic Implications.

Jeffrey Pressly1,2, Alessia Fornoni1,2.   

Abstract

Entities:  

Keywords:  PCSK9; clinical nephrology; proprotein convertase 9

Mesh：

Substances：

Year:  2022        PMID： 36176663      PMCID： PMC9416847          DOI： 10.34067/KID.0003272022

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  10 in total

1.  CD36 is a novel and potential anti-fibrogenic target in albumin-induced renal proximal tubule fibrosis.

Authors:  Yu-Lin Yang; Shyh-Horng Lin; Lea-Yea Chuang; Jinn-Yuh Guh; Tung-Nan Liao; Tao-Chen Lee; Wen-Teng Chang; Fang-Rong Chang; Min-Yuan Hung; Tai-An Chiang; Chien-Ya Hung
Journal:  J Cell Biochem       Date:  2007-06-01       Impact factor: 4.429

2.  CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD.

Authors:  Daryl M Okamura; Subramaniam Pennathur; Katie Pasichnyk; Jesús M López-Guisa; Sarah Collins; Maria Febbraio; Jay Heinecke; Allison A Eddy
Journal:  J Am Soc Nephrol       Date:  2009-02-11       Impact factor: 10.121

Review 3.  Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease.

Authors:  Borja Quiroga; Patricia Muñoz Ramos; Vicente Álvarez Chiva
Journal:  Nefrologia (Engl Ed)       Date:  2020-07-15

4.  A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

Authors:  Dirk J Blom; Tomas Hala; Michael Bolognese; Michael J Lillestol; Phillip D Toth; Lesley Burgess; Richard Ceska; Eli Roth; Michael J Koren; Christie M Ballantyne; Maria Laura Monsalvo; Kate Tsirtsonis; Jae B Kim; Rob Scott; Scott M Wasserman; Evan A Stein
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

Review 5.  Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.

Authors:  Arturo Cesaro; Vanessa Bianconi; Felice Gragnano; Elisabetta Moscarella; Fabio Fimiani; Emanuele Monda; Olga Scudiero; Giuseppe Limongelli; Matteo Pirro; Paolo Calabrò
Journal:  Biofactors       Date:  2020-01-30       Impact factor: 6.113

6.  Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Authors:  Jennifer G Robinson; Bettina S Nedergaard; William J Rogers; Jonathan Fialkow; Joel M Neutel; David Ramstad; Ransi Somaratne; Jason C Legg; Patric Nelson; Rob Scott; Scott M Wasserman; Robert Weiss
Journal:  JAMA       Date:  2014-05-14       Impact factor: 56.272

7.  PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.

Authors:  Annie Demers; Samaneh Samami; Benjamin Lauzier; Christine Des Rosiers; Emilienne Tudor Ngo Sock; Huy Ong; Gaetan Mayer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-10-22       Impact factor: 8.311

8.  Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.

Authors:  Christopher P Cannon; Bertrand Cariou; Dirk Blom; James M McKenney; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; Helen M Colhoun
Journal:  Eur Heart J       Date:  2015-02-16       Impact factor: 29.983

9.  CD36-Mediated Lipid Accumulation and Activation of NLRP3 Inflammasome Lead to Podocyte Injury in Obesity-Related Glomerulopathy.

Authors:  Jing Zhao; Hong-Liang Rui; Min Yang; Li-Jun Sun; Hong-Rui Dong; Hong Cheng
Journal:  Mediators Inflamm       Date:  2019-04-11       Impact factor: 4.711

10.  Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome.

Authors:  Jin-Ju Kim; Judith M David; Sydney S Wilbon; Javier V Santos; Devang M Patel; Anis Ahmad; Alla Mitrofanova; Xiaochen Liu; Shamroop K Mallela; Gloria M Ducasa; Mengyuan Ge; Alexis J Sloan; Hassan Al-Ali; Marcia Boulina; Armando J Mendez; Gabriel N Contreras; Marco Prunotto; Anjum Sohail; Rafael Fridman; Jeffrey H Miner; Sandra Merscher; Alessia Fornoni
Journal:  EBioMedicine       Date:  2020-12-16       Impact factor: 8.143
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.